XMED is a wholesaler in Koksijde. Private Limited, started on 16 May 2015, 2 establishments.

What is the address of XMED?

The registered office of XMED is located at Jan Van Looylaan(Kok) 5, 8670 Koksijde.

Is XMED still active?

Yes. According to the CBE (30 October 2026) XMED is active, legal situation “Normale toestand”, started on 16 May 2015.

Is XMED registered on Peppol?

Yes, XMED is registered on the Peppol network with ID 0208:0630634810.

What is the enterprise number of XMED?

The enterprise number of XMED is BE0630634810.

When was XMED founded?

XMED was founded on 16 May 2015.

Who are the directors of XMED?

According to the 2025 annual accounts, the directors of XMED are: Nuphar Tech BV, APOTHEEK DE STERRE BV.

Is XMED a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 16 May 2015; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account; 2 establishments in the CBE.

How much profit did XMED make in 2025?

XMED recorded a loss after taxes of € 7,870 in financial year 2025.

What is the revenue of XMED?

As a small company, XMED is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 40,016.

XMED (Private Limited) - Koksijde - BE0630634810

Dossier XMED, printed on 30 October 2026 from databakkes.be/en/0630634810/xmed. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Negative equity NBB

More debt than assets in 4 of the last 4 fiscal years.
Two loss years in a row NBB

Negative result in 2024 and 2025.
Tight liquidity NBB

Cash and receivables cover 7 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

XMED from Koksijde, company number BE0630634810, closed financial year 2025 with a result of € -7,870 after tax. For that financial year XMED recorded a gross margin of € 40,016 and equity of € -638,978. Compared with financial year 2024, the result moved from € -103,436 to € -7,870. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 6, 2026.

What it is worth Caution

€ -638,978

▼ € 7,870 vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -7,870

▲ 92 % less loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 27,738

▲ 25% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -1.1 million.

People and assets in 2025

Wage cost

€ 44,292

▼ 65% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 4,433

▼ 25% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 102,482

▼ 40% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Wages and social charges

€ 7,746

▲ 45% vs 2024

Wages, holiday pay and social contributions still to pay. No outstanding taxes.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ -110,570 Gross margin 2022: € -110,570 First fiscal year in the series	€ 51,968 Gross margin 2023: € 51,968 ▲ € 162,538 vs 2022 (€ -110,570) Favourable step	€ 56,184 Gross margin 2024: € 56,184 ▲ 8% vs 2023 (€ 51,968) Favourable step	€ 40,016 Gross margin 2025: € 40,016 ▼ 29% vs 2024 (€ 56,184) Unfavourable step	▼ 29%
Profit after taxes	€ -177,580 Profit after taxes 2022: € -177,580 First fiscal year in the series	€ -70,135 Profit after taxes 2023: € -70,135 ▲ € 107,445 vs 2022 (€ -177,580) Favourable step	€ -103,436 Profit after taxes 2024: € -103,436 ▼ € 33,301 vs 2023 (€ -70,135) Unfavourable step	€ -7,870 Profit after taxes 2025: € -7,870 ▲ € 95,566 vs 2024 (€ -103,436) Favourable step	▲ € 95,566
Equity	€ -457,536 Equity 2022: € -457,536 First fiscal year in the series	€ -527,671 Equity 2023: € -527,671 ▼ € 70,135 vs 2022 (€ -457,536) Unfavourable step	€ -631,107 Equity 2024: € -631,107 ▼ € 103,436 vs 2023 (€ -527,671) Unfavourable step	€ -638,978 Equity 2025: € -638,978 ▼ € 7,870 vs 2024 (€ -631,107) Unfavourable step	▼ € 7,870
Total debts	€ 615,648 Total debts 2022: € 615,648 First fiscal year in the series	€ 664,924 Total debts 2023: € 664,924 ▲ 8% vs 2022 (€ 615,648) Unfavourable step	€ 785,424 Total debts 2024: € 785,424 ▲ 18% vs 2023 (€ 664,924) Unfavourable step	€ 775,472 Total debts 2025: € 775,472 ▼ 1% vs 2024 (€ 785,424) Favourable step	▼ 1%
Cash	€ 16,875 Cash 2022: € 16,875 First fiscal year in the series	€ 23,935 Cash 2023: € 23,935 ▲ 42% vs 2022 (€ 16,875) Favourable step	€ 22,263 Cash 2024: € 22,263 ▼ 7% vs 2023 (€ 23,935) Unfavourable step	€ 27,738 Cash 2025: € 27,738 ▲ 25% vs 2024 (€ 22,263) Favourable step	▲ 25%
Retained profit	€ -912,536 Retained profit 2022: € -912,536 First fiscal year in the series	€ -982,671 Retained profit 2023: € -982,671 ▼ € 70,135 vs 2022 (€ -912,536) Unfavourable step	€ -1,086,107 Retained profit 2024: € -1,086,107 ▼ € 103,436 vs 2023 (€ -982,671) Unfavourable step	€ -1,093,978 Retained profit 2025: € -1,093,978 ▼ € 7,870 vs 2024 (€ -1,086,107) Unfavourable step	▼ € 7,870
Balance sheet total	€ 158,112 Balance sheet total 2022: € 158,112 First fiscal year in the series	€ 137,253 Balance sheet total 2023: € 137,253 ▼ 13% vs 2022 (€ 158,112) Unchanged	€ 154,317 Balance sheet total 2024: € 154,317 ▲ 12% vs 2023 (€ 137,253) Unchanged	€ 136,494 Balance sheet total 2025: € 136,494 ▼ 12% vs 2024 (€ 154,317) Unchanged	▼ 12%

Key figures of XMED, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to XMED?

What happened at XMED in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 6, 2026 New annual accounts for financial year 2025: loss of € 7,870. Source: NBB ↗
Jun 15, 2026 New establishment in Veurne. KBO
2024 Nuphar Tech BV became a director. NBB
2024 APOTHEEK DE STERRE BV became a director. NBB
May 16, 2015 New establishment in Koksijde. KBO
May 16, 2015 Start of the company according to the CBE. KBO

In short

From € 177,580 loss in 2022 to € 7,870 loss in 2025.

Paid € 15,325 in corporate taxes since 2022.

Original PDFs at the National Bank ↗

Management

Nuphar Tech BV APOTHEEK DE STERRE BV

Nascendi

XMED

Behind XMED are Nuphar Tech BV and APOTHEEK DE STERRE BV. Nuphar Tech BV is also behind Nascendi.

Directors

According to the 2025 annual accounts

Nuphar Tech BV

Director · represented by Baes Kris

Also active at: Nascendi

since 2024

APOTHEEK DE STERRE BV

Director · represented by Haghedooren Yves

since 2024

Establishments

Establishment units

Physical locations of this company

Registered office

Jan Van Looylaan(Kok) 5

8670 Koksijde

2.390.794.731

Albert I laan 31

8630 Veurne

Active since 15 June 2026

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.

All companies at this address →

NUPHAR TECH same network

€ -53,085 gross margin · 2025

Nascendi same network

€ -25,294 gross margin · 2025

HECAM

€ 25,008 gross margin · 2026

BAES-BLANCKAERT

€ 71,536 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0630.634.810

VAT number

BE 0630.634.810

Registered office

Jan Van Looylaan(Kok) 5, 8670 Koksijde

Names & denominations

XMED

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

16 May 2015

Peppol

Active · Active since 2 Jul 2025

Activities · NACE

Groothandel in farmaceutische en medische artikelen

Overige niet-gespecialiseerde detailhandel

Markt- en opinieonderzoek

Opslag

Groothandel in informatie- en communicatieapparatuur

Groothandel in elektronische en telecommunicatieapparatuur en delen daarvan

Detailhandel via postorderbedrijven of via internet

View on CBE Public ↗ Annual accounts (NBB) ↗

XMED

Warning lights

Financials

What happened to XMED?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions